🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07275827
Recruiting Phase 3

Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection

NCT07275827 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 3
Started
2026-02-01
Last updated
2026-09-09

Condition(s) studied

HELICOBACTER PYLORI INFECTIONS

Investigational drug(s) / intervention(s)

zinc sulfateVonoprazan + amoxicillin + clarithromycinAll Vonoprazan trials (12) →All Amoxicillin trials (23) →All Clarithromycin trials (11) →proton pump inhibitor + amoxicillin →

zinc sulfate: Effect of using Zinc in Helicobacter pylori Treatment

Vonoprazan + amoxicillin + clarithromycin: Effect of using Vonoprazan + amoxicillin + clarithromycin in Helicobacter pylori Treatment

proton pump inhibitor + amoxicillin: Effect of using proton pump inhibitor + amoxicillin in Helicobacter pylori Treatment

Study summary

this Study Evaluating Safety and Effectiveness of (Proton Pump Inhibitor versus Vonoprazan) Based Triple Therapy with or without Zinc to Eradicate H. pylori Infection

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \> 18. * Both males and females. * Patients who are positive for H.pylori infection by non-invasive Stool Antigen Test (SAT). Exclusion Criteria: * Prior H. pylori treatment: Previous treatment for H. pylori infection. * Allergies: Known allergies to study medications or components. * Patients cannot finish treatment course. * Pregnant and Lactating Women. * Patients with Kidney disease and eGFR \< 30ml/min. * Patients with Liver disease with Child-Pugh B or C.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
National Liver Institute Shibīn al Kawm Egypt Recruiting

More Tanta University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07275827 on ClinicalTrials.gov ↗ ← All trials in Egypt